PCAR 019

Drug Profile

PCAR 019

Alternative Names: Anti-CD19 CAR T cells - PersonGen BioTherapeutics; Anti-CD19 CAR-transduced T cells - PersonGen BioTherapeutics; Anti-CD19 chimeric antigen receptor T cell therapy - PersonGen Biomedicine; PCAR019

Latest Information Update: 03 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PersonGen Biomedicine
  • Class Antineoplastics; CAR-T cell therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Leukaemia; Lymphoma

Most Recent Events

  • 01 Oct 2016 PersonGen BioTherapeutics initiates a phase-I/II trial in Lymphoma and Leukaemia (In adults, Second-line therapy or greater) in China (Parenteral) (NCT02819583)
  • 05 Jul 2016 PersonGen Biomedicine plans a phase I/II trial for Cancer in China (NCT02819583)
  • 01 Jul 2016 Phase-I/II clinical trials in Lymphoma and Leukaemia (In adolescents, In adults, Second-line therapy or greater) in China (Parenteral) (NCT02851589)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top